FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a composition comprising an effective amount of at least one microRNA inhibitor involved in angiogenesis and exhibiting anti-angiogenic activity, or a precursor thereof, wherein said inhibitor is microencapsulated in polymer biodegradable and biocompatible microspheres, and can be used in medicine.
EFFECT: invention makes it possible to prevent ventricular remodeling after an acute myocardial infarction with intracoronary administration.
23 cl, 12 dwg, 5 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION COMPRISING microRNA-100 AND USE THEREOF IN MODULATING GROWTH OF BLOOD VESSELS AND ENDOTHELIUM INFLAMMATION | 2010 |
|
RU2586531C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| COMPOSITIONS AND METHODS FOR TREATING HAEMOGLOBINOPATHIES | 2015 |
|
RU2707540C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| METHOD OF SELECTING FOOD DIET, PROVIDING OBTAINING MILK, POSSESSING IMMUNOSTIMULATING ACTION | 2010 |
|
RU2545377C2 |
| MICRORNA-124 AS BIOMARKER | 2014 |
|
RU2687366C2 |
| MIRNK-19A/19B FOR USE IN TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH BONE LOSS OR DECREASED MUSCLE FUNCTION | 2018 |
|
RU2770369C2 |
| MIR-155 INHIBITORS FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL) | 2016 |
|
RU2718534C2 |
| METHODS OF TREATING POLYCYSTIC KIDNEY DISEASE | 2016 |
|
RU2742300C2 |
